We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma
News

GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma

GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma
News

GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GlaxoSmithKline (GSK) and Theravance, Inc. have announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* (fluticasone furoate "FF"/vilanterol "VI") in patients with chronic obstructive pulmonary disease (COPD) and of all but one of the pivotal studies in patients with asthma.

For COPD, GSK intends to submit regulatory applications in the US and Europe in mid-2012. For asthma, GSK plans to submit an application in Europe in mid-2012 and will continue discussions with the FDA on the regulatory requirements for a US asthma indication.

Darrell Baker, SVP Respiratory Portfolio Optimisation Leader at GSK said: "We are pleased to have reached this milestone for Relovair™, one of the important assets in our respiratory development portfolio. Having undertaken an initial assessment of these data we believe they support our plan to seek global approvals of this once-daily medicine for the treatment of patients with COPD and asthma."

Rick E Winningham, Chief Executive Officer of Theravance said: "We are very excited with the new data and GSK's plan to submit regulatory applications for Relovair™ in the US and Europe this year. Relovair™ is one of our three respiratory programs with GSK."

The full results of these pivotal studies will be presented at future scientific meetings.

Advertisement